Patricia A. Martin
CIK: 0001916764
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (23 total)
- Oct 12, 2026ANTX
AN2 Therapeutics, Inc.
Award(A)Direct389 shares- - Sep 23, 2026CYPH
CYPHERPUNK TECHNOLOGIES INC.
Sale(S)Direct50K shares at avg. $3.86$193K - Jul 10, 2026ANTX
AN2 Therapeutics, Inc.
Award(A)Direct766 shares- - Jul 1, 2026CYPH
CYPHERPUNK TECHNOLOGIES INC.
Award(A)DirectRestricted Stock Units
75K shares- - Apr 10, 2026ANTX
AN2 Therapeutics, Inc.
Award(A)Direct1.2K shares- - Mar 19, 2026ANTX
AN2 Therapeutics, Inc.
Disposition(D)DirectStock Option (right to buy)
10.4K shares- - Mar 19, 2026ANTX
AN2 Therapeutics, Inc.
Disposition(D)DirectStock Option (right to buy)
23.7K shares- - Mar 19, 2026ANTX
AN2 Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
25K shares- - Mar 19, 2026ANTX
AN2 Therapeutics, Inc.
Disposition(D)DirectStock Option (right to buy)
25K shares- - Mar 19, 2026ANTX
AN2 Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
10.4K shares- - Mar 19, 2026ANTX
AN2 Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
23.7K shares- - Mar 13, 2026CYPH
CYPHERPUNK TECHNOLOGIES INC.
Exercise(M)Direct94.1K shares- - Mar 13, 2026CYPH
CYPHERPUNK TECHNOLOGIES INC.
Exercise(M)Direct74.7K shares- - Feb 20, 2026ANTX
AN2 Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
20.4K shares- - Jan 12, 2026ANTX
AN2 Therapeutics, Inc.
Award(A)Direct3.7K shares- - Dec 23, 2025CYPH
CYPHERPUNK TECHNOLOGIES INC.
Award(A)DirectRestricted Stock Units
94.1K shares- - Nov 11, 2025CYPH
CYPHERPUNK TECHNOLOGIES INC.
Award(A)DirectRestricted Stock Units
74.7K shares- - Oct 10, 2025ANTX
AN2 Therapeutics, Inc.
Award(A)Direct3.3K shares- - Jul 10, 2025ANTX
AN2 Therapeutics, Inc.
Award(A)Direct3.8K shares- - May 22, 2025ANTX
AN2 Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
19.1K shares- - Apr 10, 2025ANTX
AN2 Therapeutics, Inc.
Award(A)Direct3.1K shares- - Dec 19, 2024ANTX
AN2 Therapeutics, Inc.
Award(A)Direct3.2K shares- - Oct 2, 2024LPTX
LEAP THERAPEUTICS, INC.
Award(A)DirectStock Option (Right to Buy)
25K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 12, 2026 |  ANTX AN2 Therapeutics, Inc. | Award(A) | 389 | - | $0 | Direct |
| Sep 23, 2026 |  CYPH CYPHERPUNK TECHNOLOGIES INC. | Sale(S) | 50,000 | $3.86 | $193,000 | Direct |
| Jul 10, 2026 | ANTX AN2 Therapeutics, Inc. | Award(A) | 766 | - | $0 | Direct |
| Jul 1, 2026 | CYPH CYPHERPUNK TECHNOLOGIES INC. | Award(A) Restricted Stock Units | 75,000 | - | - | Direct |
| Apr 10, 2026 | ANTX AN2 Therapeutics, Inc. | Award(A) | 1,192 | - | $0 | Direct |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | Disposition(D) Stock Option (right to buy) | 10,362 | - | - | Direct |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | Disposition(D) Stock Option (right to buy) | 23,742 | - | - | Direct |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 24,999 | - | - | Direct |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | Disposition(D) Stock Option (right to buy) | 24,999 | - | - | Direct |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 10,362 | - | - | Direct |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 23,742 | - | - | Direct |
| Mar 13, 2026 | CYPH CYPHERPUNK TECHNOLOGIES INC. | Exercise(M) | 94,050 | - | $0 | Direct |
| Mar 13, 2026 | CYPH CYPHERPUNK TECHNOLOGIES INC. | Exercise(M) | 74,700 | - | $0 | Direct |
| Feb 20, 2026 | ANTX AN2 Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 20,400 | - | - | Direct |
| Jan 12, 2026 | ANTX AN2 Therapeutics, Inc. | Award(A) | 3,650 | - | $0 | Direct |
| Dec 23, 2025 | CYPH CYPHERPUNK TECHNOLOGIES INC. | Award(A) Restricted Stock Units | 94,050 | - | - | Direct |
| Nov 11, 2025 | CYPH CYPHERPUNK TECHNOLOGIES INC. | Award(A) Restricted Stock Units | 74,700 | - | - | Direct |
| Oct 10, 2025 | ANTX AN2 Therapeutics, Inc. | Award(A) | 3,274 | - | - | Direct |
| Jul 10, 2025 | ANTX AN2 Therapeutics, Inc. | Award(A) | 3,750 | - | - | Direct |
| May 22, 2025 | ANTX AN2 Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 19,111 | - | - | Direct |
| Apr 10, 2025 | ANTX AN2 Therapeutics, Inc. | Award(A) | 3,065 | - | - | Direct |
| Dec 19, 2024 | ANTX AN2 Therapeutics, Inc. | Award(A) | 3,166 | - | $0 | Direct |
| Oct 2, 2024 |  LPTX LEAP THERAPEUTICS, INC. | Award(A) Stock Option (Right to Buy) | 25,000 | - | - | Direct |
1-23 of 23 transactions
About Martin Patricia A.
Martin Patricia A. (SEC CIK 0001916764) files insider reports with the SEC as Director of AN2 Therapeutics, Inc. (ANTX) and Director of CYPHERPUNK TECHNOLOGIES INC. (CYPH).
Signal8 holds 17 ownership filings by Martin Patricia A., all Form 4s, filed between Oct 4, 2024 and Oct 13, 2026. Those filings report 23 transactions, from Oct 2, 2024 to Oct 12, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Martin Patricia A.'s filings is in MENLO PARK, CA.
Recent filings by Martin Patricia A.
- Oct 12, 2026: Grant or award of ANTX shares (Form 4, code A).
- Sep 23, 2026: Open-market sale of CYPH shares (Form 4, code S).
- Jul 10, 2026: Grant or award of ANTX shares (Form 4, code A).
- Jul 1, 2026: Grant or award of CYPH derivative securities (Form 4, code A).
- Apr 10, 2026: Grant or award of ANTX shares (Form 4, code A).
Other insiders filing for AN2 Therapeutics, Inc. (ANTX)
- Marks Gilbert Lynn, Director
- Aziz Kabeer, Director
- Trenor Cameron C. III, Chief Medical Officer
- Readnour Robin Shane, Director
- Williams Sarah Joanne, Principal Accounting Officer
- FitzPatrick Margaret M, Director